Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oppenheimer Initiates Coverage On Corebridge Financial with Outperform Rating, Announces Price Target of $30

Oppenheimer analyst Chris Kotowski initiates coverage on Corebridge Financial (NYSE:CRBG) with a Outperform rating and announces Price Target of $30.
byBenzinga Newsdesk
October 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Oppenheimer analyst Chris Kotowski initiates coverage on Corebridge Financial (NYSE:CRBG) with a Outperform rating and announces Price Target of $30.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Eledon Pharmaceuticals Received FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

By Charles Gross
August 1, 5:14 AM
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that the U.S.

ELDN